FDA has accepted to review Pfizer’s (NYSE: PFE) 20-valent pneumococcal conjugate vaccine for the prevention against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, in adults ages 18 years and older. The agency will review the vaccine on a priority basis with a decision expected in June 2021.
Click here for the full Trefis coverage of Pfizer
- Pfizer Vaccine Updates: Possibly Easier Storage, Efficacy Against South African Strain
- Buy Pfizer Stock Or JNJ For Vaccine Run?
- What The Approval Of The Covid Vaccine In The U.K Means For Pfizer Stock
- Here’s Why Pfizer Stock Looks Inviting At $39 Levels
- Forecast of the Day: Pfizer’s Immunology Drugs Revenue
- Why Pfizer’s Covid-19 Vaccine Is Unlikely To Move The Needle For The Stock
Looking for a balanced portfolio to invest in? Here’s a high-quality portfolio to beat the market, with over 100% return since 2016, versus 55% for the S&P 500. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams
